

Tralieve 20 mg chewable tablets for dogs

Authorised

- Tramadol hydrochloride

Product identification

Medicine name:

Tralieve 20 mg chewable tablets for dogs

Active substance:

Tramadol hydrochloride

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Tramadol hydrochloride
20.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN02AX02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Norway

Available in:

Norway

Package description:

Cardboard box of 3 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 1 Aluminium - PVC/PE/PVDC blister of 10 tablets.

Cardboard box containing 10 separate cardboard boxes, each containing 3 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 2 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 10 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 4 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 5 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 9 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 8 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 7 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 6 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 25 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Dechra Regulatory B.V.

Marketing authorisation date:

8/03/2019

Manufacturing sites for batch release:

Lelypharma B.V.

Genera d.d.

Responsible authority:

Norwegian Medical Products Agency

Authorisation number:

17-11628

Date of authorisation status change:

1/04/2022

Reference member state:

Netherlands

Procedure number:

NL/V/0231/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.